Table 3.
Receiver-operating characteristics of validation set
| All Stages | Stage I | Stage II | Stage III | ||
|---|---|---|---|---|---|
| N | 30/24 | 7/24 | 9/24 | 14/24 | |
| CA19-9 (≥ 55 U/ml) | AUC | 0.80 | 0.69 | 0.87 | 0.83 |
| 95 % CI | 0.70 | 0.49 | 0.72 | 0.69 | |
| 0.89 | 0.90 | 1.00 | 0.96 | ||
| THBS2 (≥ 42 ng/ml) | AUC | 0.73 | 0.69 | 0.76 | 0.71 |
| 95 % CI | 0.63 | 0.49 | 0.58 | 0.56 | |
| 0.83 | 0.90 | 0.93 | 0.86 | ||
| cfDNA (ng/ml) | AUC | 0.90 | 0.89 | 0.97 | 0.84 |
| 95 % CI | 0.81 | 0.77 | 0.92 | 0.69 | |
| 0.98 | 1.00 | 1.00 | 0.99 | ||
| CA19-9 (≥ 55 U/ml) + THBS2 (≥ 42 ng/ml) | AUC | 0.87 | 0.89 | 0.86 | 0.86 |
| 95 % CI | 0.78 | 0.74 | 0.71 | 0.73 | |
| 0.96 | 1.00 | 1.00 | 0.99 | ||
| CA19-9 (≥ 55 U/ml) + THBS2 (≥ 42 ng/ml) + cfDNA (ng/ml) | AUC | 0.94 | 0.90 | 0.96 | 0.94 |
| 95 % CI | 0.88 | 0.78 | 0.91 | 0.87 | |
| 1.00 | 1.00 | 1.00 | 1.00 | ||
| p-value | 0.0013 | 0.0143 | 0.1424 | 0.0549 |
AUC=Area under curve, CI=Confidence interval, p-values are calculated for CA19-9 (≥ 55 U/ml) + THBS2 (≥ 42 ng/ml) + cfDNA (ng/ml) model versus established marker CA19-9.